SOLO COVID-19 | Preclinical services of COVID-19 | Oncodesign

Infectious diseases

Oncodesign Services has ABSL2 and ABSL3 facilities and local partnerships allowing infectious disease models to be run in rodent and NHP. In addition, we have in vitro laboratories certified to handle BSL2 and BSL3 pathogens. Oncodesign Services can offer integrated drug discovery and preclinical programs (INPACT) for antivirals, from chemistry, screening to in vivo proof of concept. With all the capabilities under the same roof, we can offer fast cycle times.

COVID-19

Oncodesign Services offers a complete portfolio of in vivo & in vitro solutions to evaluate products against SARS-CoV-2 infection. This offer was swiftly deployed in 2020, allowing – with rigor and safety – the implementation of specific in vitro and in vivo pharmacology studies to evaluate new prophylactic, therapeutic or vaccinal approaches to fight COVID-19.

MORE DETAILS ABOUT OUR COVID-19 SERVICES

Other pathogens

Through the Infectious Disease Model and Innovative Therapies (IDMIT) center (CEA, Fontenay, Paris, France) as a partner, Oncodesign Services can offer NHP studies in other pathogens such as HIV, Tuberculosis, CMV and monkeypox… Please ask us about your pathogen of interest.

We also propose the TC-1 syngeneic (C57BL/6) mouse tumor model (HPV+) for the evaluation of HPV-targeting therapies. In this model, the recipient mice mount a HPV specific CD8+ T cell response that can monitored by flow cytometry (Dextramer HPV-E7 staining).

 

Typical assays offered for viral studies: viral (target?) expression by cell imaging, viral-induced cytotoxicity, antibody neutralization, compound binding, inhibition of infectivity and cytokine expression.

Oncodesign Services is certified to handle a number of pathogens in vitro already:

  • Herpes (HSV-1 and -2)
  • Respiratory syncytial virus (RSV)
  • Arboviruses (Chikungunya, Ross river, Dengue, Semliki, Mayaro, O’nyong nyong, Zika)
  • Human immunodeficiency virus (HIV-1 and -2)
  • Influenza A/H1N1
  • SARS-CoV-2 with different variants (G614, alpha, beta, gamma, delta, omicron)
  • Soon: human rhinovirus and parainfluenza3

Targeted cells for each pathogen are available and validated. Classical protocol of infection is followed. Readouts include cell viability (cytotoxicity of candidate without virus), colorimetric assay when cytopathogen effects exhibited, viral replication with commercial kit when available, viral load by RT-qPCR (relative value) and digital PCR (absolute value in number of viral copy), possibility of immufluorescence with HCS imaging (ImageXpress® Pico technology).

Infectious - Antibody neutralization assay COVID Vero6